Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Phelinun

PHELINUN 50 mg powder and solvent for concentrate for solution for infusion PHELINUN 200 mg powder and solvent for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9–10

HOS-144861 · Präparat HOS-099276

9 The adverse drug reactions (ADRs) described in this section were identified from information included in other melphalan containing products, the screening of the published literature and the European database EudraVigilance concerning the use of melphalan as part of combination regimens for allo-HSCT setting. With the exception of Stevens-Johnson syndrome and Toxic epidermal necrolysis identified for only one patient, ADRs reported for at least two patients have been captured in the table below. Frequencies are described as very common (1/10), common (1/100 to <1/10), uncommon (1/1 000 to <1/100), rare (1/10 000 to <1/1,000), very rare (<1/10 000), and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.